Alcobra Ltd. To Release Third Quarter Financial Results And Host Corporate Update Conference Call & Webcast On November 15

TEL AVIV, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the third quarter ended September 30, 2016 before the market open, and will host a corporate update conference call and webcast on Tuesday, November 15, at 8:30 am Eastern Time.
 
Conference Call & Webcast
Tuesday, Nov 15, 2016 @ 8:30 am Eastern Time
Domestic:   855-469-0611
International:   484-756-4341
Passcode:   9001229
Webcast:   http://www.alcobra-pharma.com/events.cfm
 
Replays available through November 29, 2016
Domestic:   855-859-2056
International:   404-537-3406
Passcode:   9001229

About Alcobra Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor ContactsLifeSci Advisors, LLCMichael Rice646-597-6979mrice@lifesciadvisors.comMedia InquiriesSam Brown, Inc.Mike Beyer773-463-4211mikebeyer@sambrown.comIsrael Investor Contact:Alcobra Investor RelationsDebbie Kaye+972-72 2204661debbie@alcobra-pharma.com

Primary Logo

If you liked this article you might like

Johnson & Johnson Shuts Insulin Pump Business, Inks Other Deals

Johnson & Johnson Shuts Insulin Pump Business, Inks Other Deals

Alcobra Shares Plummet as ADHD Drug Fails

Alcobra Shares Plummet as ADHD Drug Fails

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Alcobra (ADHD) Stock Sliding, Downgraded After FDA Clinical Hold

Alcobra (ADHD) Stock Sliding, Downgraded After FDA Clinical Hold

Alcobra (ADHD) Stock Tumbles on FDA Clinical Hold, Cantor Remains Bullish

Alcobra (ADHD) Stock Tumbles on FDA Clinical Hold, Cantor Remains Bullish